Barclays has revised its price target for Clorox (CLX, Financial), lowering it to $134 from the previous $139, while maintaining an Underweight rating on the stock. This adjustment comes as part of an earnings preview for the consumer staples sector, which is facing ongoing challenges.
The firm highlights a persistent consumer slowdown, which was noticeable even before what has been termed as "Liberation Day." There is skepticism about whether the transitional 90-day period will revitalize these categories.
Although the pressures related to tariffs have lessened, Barclays notes that the consumer staples market is still experiencing substantial uncertainty. As Clorox prepares to release its first-quarter earnings, these factors are likely to weigh on its performance and investor outlook.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 17 analysts, the average target price for Clorox Co (CLX, Financial) is $161.48 with a high estimate of $189.00 and a low estimate of $138.00. The average target implies an upside of 14.60% from the current price of $140.90. More detailed estimate data can be found on the Clorox Co (CLX) Forecast page.
Based on the consensus recommendation from 21 brokerage firms, Clorox Co's (CLX, Financial) average brokerage recommendation is currently 3.0, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Clorox Co (CLX, Financial) in one year is $148.83, suggesting a upside of 5.63% from the current price of $140.9. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Clorox Co (CLX) Summary page.
